Accéder au contenu
Merck

Utilizing mouse optic nerve crush to examine CNS remyelination.

STAR protocols (2021-11-18)
Tracey A C S Suter, Jing Wang, Huyan Meng, Zhigang He
RÉSUMÉ

In developing pro-myelination treatment, an important hurdle is the lack of reliable animal models for assessing de novo myelination in disease settings. We recently showed that regenerated axons in injured optic nerves fail to be myelinated, providing an animal model for this purpose. Here, we describe procedures to promote axonal regeneration, administer optic nerve crush, and assess oligodendrocyte differentiation and maturation into myelination-competent oligodendrocytes. This protocol allows for testing the efficacy of remyelination treatments in an in vivo central nervous system (CNS). For complete details on the use and execution of this protocol, please refer to Wang et al. (2020) and Bei et al. (2016).

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
Anticorps anti-Aspa/Nur7, from rabbit, purified by affinity chromatography
Sigma-Aldrich
Anticorps anti-glycoprotéine associée à la myéline, clone 513, clone 513, Chemicon®, from mouse
Sigma-Aldrich
Anticorps anti-Olig2, clone 211F1.1, conjugué à l'Alexa Fluor 488 | MABN50A4, clone 211F1.1, from mouse, ALEXA FLUOR 488